Table 2.
Patient characteristics
| Characteristics | Number of patients (n = 12) |
|---|---|
| Age, years | |
| Median | 57 |
| Range | 28–73 |
| Race | |
| Caucasian | 10 |
| Black | 1 |
| Asian | 1 |
| ECOG Performance status | |
| 0 | 6 |
| 1 | 6 |
| Location of disease | |
| Visceral | 10 |
| Non-visceral | 2 |
| Hormone-receptor (ER, PR, or both) positive/HER-2 neg | 5 |
| HER2-pos (ER-pos; ER-neg) | 4 (3; 1) |
| Triple-negative (ER,PR,HER-2 negative) | 3 |
| Number of prior regimens for metastatic disease | |
| 1 | 2a |
| 2 | 3 |
| 3 | 3 |
| ≥4 | 1 |
| Median no. of regimens for metastatic disease (range) | 2 (0–8) |
| No. of prior taxane regimens | |
| Any setting | 10 |
| Metastatic setting | 7 |
| Median number of prior taxane regimens | |
| Any setting (range) | 1 (0–2) |
| Metastatic setting (range) | 0 (0–2) |
ER estrogen receptor, PR progesterone receptor, ECOG Eastern Cooperative Oncology Group
a
1 patient underwent chemo-embolization to liver twice also